RISE CAB training package
>
Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

6 April 2023

This journal article from Antimicrobial Agents and Chemo Therapy shares an extended report on HIV infections that occurred up to 1 year after study unblinding (18 in the CAB arm and 34 in the TDF-FTC arm).

Topic(s): Monitoring & Evaluation

Product(s): Cabotegravir

Population(s): Cisgender Men, Trans Women

Region(s): East Asia & Pacific, Latin America & Caribbean, North America, South Asia, Sub-Saharan Africa

Format(s): Journal Article

Source(s): Antimicrobial Agents and Chemo Therapy

Type: External Link

Visit

Featured Resources

Document

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, March 2024

This document summarises key takeaways from a March 2024 BioPIC Think Tank to ensure modellers and implementation science researchers remain aligned on the latest cabotegravir for PrEP data and evidence.
Document

Coordinating Implementation Science: Taking Stock of PrEP Evidence

This document summarises key takeaways from the BioPIC Think Tank held in March 2024 to review existing PrEP evidence and evidence gaps to date.
Document

Opportunities for Pharmacist-Delivered Injectable PrEP in the USA

These Quick Take briefings from Georgetown University’s O’Neill Institute for National and Global Health Law provide insights on barriers and opportunities for pharmacist-administered injectable PrEP in the USA, including delivery via mobile pharmacies.
Spreadsheet

MOSAIC – PrEP Site Implementation and New Product Readiness Assessment Tool

This tool is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation. Additionally, this tool is designed to inform preparations for new PrEP product introduction (CAB PrEP, PrEP ring, or both) according to national priorities. Findings from readiness assessment visits using this tool…
Document

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.
Document

CAB PrEP Introduction Situation Analysis – Zimbabwe – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform. It aims to clarify critical steps for the introduction of biomedical HIV prevention products.
Document

CATALYST Interim Learnings (May-November 2023)

In this first interim analysis, the MOSAIC team provides key learnings from preparing for the delivery of PrEP choice, a summary of challenges experienced in implementing the enhanced service delivery model and the solutions introduced, programmatic considerations for countries preparing to introduce new PrEP methods, and a list of publicly accessible tools and resources used…
Document

Coordinating Implementation Science for CAB for PrEP: Early Insights from EBONI and PILLAR

This document summarises key takeaways from the BioPIC Think Tank on early insights from ViiV Healthcare’s two cabotegravir for PrEP implementation studies- EBONI and PILLAR.
Document

CAB PrEP Introduction Situation Analysis – Eswatini – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.
Document

CAB PrEP Introduction Situation Analysis – Kenya – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.